SCHEMBL4834086

SCHEMBL4834086

CCOC(=O)c1cn(Cc2ccccc2)nc1-c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
LMNA P02545 2/20 0.51
ALDH1A1 P00352 2/20 0.51
KMT2A Q03164 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
RXFP1 Q9HBX9 1/20 0.50
TEAD2 Q15562 1/20 0.49
F2RL3 Q96RI0 1/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
MAPT P10636 1/20 0.49
MEN1 O00255 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CA12 O43570 1/20 0.47
CA9 Q16790 1/20 0.47
KLKB1 P03952 1/20 0.47
KLK1 P06870 1/20 0.47
GRM2 Q14416 1/20 0.47
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3493198 0.92 KMT2A (0.58) MAPK1NPSR1LMNAALDH1A1KMT2A
SCHEMBL5380988 0.91 MMP13 (0.49) MAPK1NPSR1LMNAALDH1A1KMT2A
SCHEMBL5385608 0.86 MAPK1 (0.54) MAPK1NPSR1LMNAALDH1A1KMT2A
SCHEMBL27612936 0.84 ALDH1A1 (0.65) LMNAALDH1A1KMT2ASMN1; SMN2NPC1
SCHEMBL15750457 0.83 NPC1 (0.51) MAPK1NPSR1LMNAALDH1A1KMT2A
SCHEMBL5377556 0.83 KMT2A (0.52) MAPK1NPSR1LMNAALDH1A1KMT2A
SCHEMBL16246850 0.83 KMT2A (0.49) MAPK1NPSR1LMNAALDH1A1KMT2A
SCHEMBL7965075 0.81 NPSR1 (0.77) MAPK1NPSR1ALDH1A1KMT2ANPC1
SCHEMBL20027638 0.80 MAPK1 (0.60) MAPK1NPSR1LMNAALDH1A1KMT2A
SCHEMBL4852276 0.79 ALDH1A1 (0.59) MAPK1LMNAALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed
EP-1556032-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY Takeda Pharmaceutical Company Limited (JP) 2005-07-27 EP disclosed
WO-2004039365-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 MAPK1 1214/4885NPSR1 339/4885LMNA 2405/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 MAPK1 1214/4885NPSR1 339/4885LMNA 2405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.